Abstract:In our continuing efforts to develop novel c-Met inhibitors as potential anticancer candidates, a series of new N-sulfonylamidine derivatives were designed, synthesized via Cu-catalyzed multicomponent reaction (MCR) as the key step, and evaluated for their in vitro biological activities against c-Met kinase and four cancer cell lines (A549, HT-29, MKN-45 and MDA-MB-231). Most of the target compounds showed moderate to significant potency at both the enzyme-based and cell-based assay and possessed selectivity for A549 and HT-29 cancer cell lines. The preliminary SAR studies demonstrated that compound 26af (c-Met IC50 = 2.89 nM) was the most promising compound compared with the positive foretinib, which exhibited the remarkable antiproliferative activities, with IC50 values ranging from 0.28 to 0.72 μM. Mechanistic studies of 26af showed the anticancer activity was closely related to the blocking phosphorylation of c-Met, leading to cell cycle arresting at G2/M phase and apoptosis of A549 cells by a concentration-dependent manner. The promising compound 26af was further identified as a relatively selective inhibitor of c-Met kinase, which also possessed an acceptable safety profile and favorable pharmacokinetic properties in BALB/c mouse. The favorable drug-likeness of 26af suggested that N-sulfonylamidines may be used as a promising scaffold for antitumor drug development. Additionally, the docking study and molecular dynamics simulations of 26af revealed a common mode of interaction with the binding site of c-Met. These positive results indicated that compound 26af is a potential anti-cancer candidate for clinical trials, and deserves further development as a selective c-Met inhibitor.

Design, Synthesis and Biological Evaluation of Novel α‐Acyloxycarboxamide‐Based Derivatives as c‐Met Inhibitors

Design, Synthesis and Biological Evaluation of Novel 4-Phenoxypyridine Based 3-Oxo-3,4-dihydroquinoxaline-2-carboxamide Derivatives As Potential C-Met Kinase Inhibitors.

Structure-guided design and development of novel N-phenylpyrimidin-2-amine derivatives as potential c-Met inhibitors

Design, synthesis and biological evaluation of novel N-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction

Structure-based Discovery of Novel 4-(2-fluorophenoxy)quinoline Derivatives As C-Met Inhibitors Using Isocyanide-Involved Multicomponent Reactions.

Design, Synthesis and Biological Evaluation of Novel N-[4-(2-fluorophenoxy)pyridin-2-yl]cyclopropanecarboxamide Derivatives As Potential C-Met Kinase Inhibitors

Design, Synthesis and Biological Evaluation of Novel 4-Phenoxypyridine Derivatives Containing Semicarbazones Moiety As Potential C-Met Kinase Inhibitors.

Design, synthesis and biological evaluation of novel <i>N</i>-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction

Design, Synthesis, and Biological Evaluation of 4-Phenoxyquinoline Derivatives As Potent C-Met Kinase Inhibitor

Design, Synthesis and Biological Evaluation of Novel 4-Phenoxyquinoline Derivatives Containing 3-Oxo-3,4-dihydroquinoxaline Moiety As C-Met Kinase Inhibitors

Design and Optimization of Novel 4-(2-fluorophenoxy)quinoline Derivatives Bearing a Hydrazone Moiety As C-Met Kinase Inhibitors.

Design, Synthesis and Biological Evaluation of Sulfonylamidines As Potent C-Met Inhibitors by Enhancing Hydrophobic Interaction.

Design, synthesis and biological evaluation of 4-(4-aminophenoxy)picolinamide derivatives as potential antitumor agents

Structure–activity relationship study of novel quinazoline-based 1,6-naphthyridinones as MET inhibitors with potent antitumor efficacy

Design, Synthesis and Biological Evaluation of 4-Phenoxy- Pyridine/Pyrimidine Derivatives as Dual VEGFR-2/c-Met Inhibitors

Design, Synthesis, and Biological Evaluation of [1,2,4]triazolo[4,3-a] Pyrazine Derivatives as Novel Dual c-Met/VEGFR-2 Inhibitors

Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.

Structure-based design, synthesis, and evaluation of 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine derivatives as novel c-Met inhibitors

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

Synthesis And C-Met Kinase Inhibition Of 3,5-Disubstituted And 3,5,7-Trisubstituted Quinolines: Identification Of 3-(4-Acetylpiperazin-1-Y1)-5-(3-Nitrobenzylamino)-7-(Trifluoromethyl)Qui Noline As A Novel Anticancer Agent

Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors